LTFS
PTGX icon

Ladenburg Thalmann Financial Services’s Protagonist Therapeutics PTGX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1K Hold
83
– – ﹤0.01% 5220
2019
Q3 		$1K Buy
+83
New +$1.05K ﹤0.01% 5147

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ladenburg Thalmann Financial Services's PTGX Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its Protagonist Therapeutics (PTGX) position steady in Q4 2019 at 83 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #5220.

Ladenburg Thalmann Financial Services first reported a position in PTGX in Q3 2019 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold PTGX as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 83 shares of Protagonist Therapeutics worth $1K as of Q4 2019.
  • Ladenburg Thalmann Financial Services left its Protagonist Therapeutics share count unchanged in Q4 2019.
  • Protagonist Therapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5220 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Protagonist Therapeutics in Q3 2019 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.